公开(公告)号：US20240358831A1

公开(公告)日：2024-10-31

申请号：US18685736

申请日：2022-08-24

Applicant: IMMATICS US, INC. ,  Immatics Biotechnologies GmbH

Inventor： Stefanie SPALT ,  Claudia WAGNER ,  Dominik MAURER ,  Heiko SCHUSTER ,  Steffen WALTER

IPC: A61K39/00 ,  C07K14/74 ,  C12N5/0783

CPC classification number: A61K39/4632 ,  A61K39/4611 ,  C07K14/70539 ,  C12N5/0636 ,  C12N2502/11

Abstract: The present invention relates to a method for selecting an immune cell expressing on its surface an antigen-binding protein specifically binding to a complex of a peptide A (PA) and a Major Histocompatibility Complex (MHC) molecule, comprising the steps of (i) providing a plurality of immune cells expressing different antigen-binding proteins; (ii) contacting the plurality of immune cells with a first composition comprising a complex 1A, comprising a MHC molecule 1 (M1) and a peptide A (PA), and a complex 1X, comprising M1 and a peptide B (PB); (iii) contacting the plurality of immune cells with a second composition comprising a complex 2A, comprising a MHC molecule 2 (M2) and PA, and a complex 2X, comprising M2 and a peptide C (PC); (iv) selecting from the plurality of immune cells a cell expressing an antigen binding protein that specifically binds to complex 1A, wherein complexes 1X and 2X, but not 1A and 2A, dissociate upon stimulation with a defined chemical or physical stimulus; and wherein the amino acid sequences of PB and PC differ in at least one amino acid. The invention further relates to an immune cell selected by the method according to the invention, a method of treatment using said immune cell, a kit for selecting a cell expressing on its surface an antigen-binding protein, and a peptide suitable for use in the method according to the invention.

公开(公告)号：US20240239867A1

公开(公告)日：2024-07-18

申请号：US18433955

申请日：2024-02-06

Applicant: Immatics Biotechnologies GmbH

Inventor： Jens HUKELMANN ,  Heiko SCHUSTER ,  Lena WULLKOPF ,  Christoph SCHRAEDER ,  Jens FRITSCHE ,  Daniel Johannes KOWALEWSKI ,  Michael ROEMER ,  Oliver SCHOOR

IPC: C07K14/725 ,  A61K35/17 ,  A61K38/00 ,  C07K14/74 ,  C07K16/28

CPC classification number: C07K14/7051 ,  A61K35/17 ,  C07K14/70539 ,  C07K16/2833 ,  A61K38/00 ,  C07K2319/30

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240218044A1

公开(公告)日：2024-07-04

申请号：US18421973

申请日：2024-01-24

Applicant: Immatics Biotechnologies GmbH

Inventor： Jens HUKELMANN ,  Heiko SCHUSTER ,  Lena WULLKOPF ,  Christoph SCHRAEDER ,  Jens FRITSCHE ,  Daniel Johannes KOWALEWSKI ,  Michael ROEMER ,  Oliver SCHOOR

IPC: C07K14/725 ,  A61K35/17 ,  A61K38/00 ,  C07K14/74 ,  C07K16/28

CPC classification number: C07K14/7051 ,  A61K35/17 ,  C07K14/70539 ,  C07K16/2833 ,  A61K38/00 ,  C07K2319/30

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240166714A1

公开(公告)日：2024-05-23

申请号：US18433913

申请日：2024-02-06

Applicant: Immatics Biotechnologies GmbH

Inventor： Jens HUKELMANN ,  Heiko SCHUSTER ,  Lena WULLKOPF ,  Christoph SCHRAEDER ,  Jens FRITSCHE ,  Daniel Johannes KOWALEWSKI ,  Michael ROEMER ,  Oliver SCHOOR

IPC: C07K14/725 ,  A61K35/17 ,  C07K14/74 ,  C07K16/28

CPC classification number: C07K14/7051 ,  A61K35/17 ,  C07K14/70539 ,  C07K16/2833 ,  A61K38/00

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240166712A1

公开(公告)日：2024-05-23

申请号：US18433852

申请日：2024-02-06

Applicant: Immatics Biotechnologies GmbH

Inventor： Jens HUKELMANN ,  Heiko SCHUSTER ,  Lena WULLKOPF ,  Christoph SCHRAEDER ,  Jens FRITSCHE ,  Daniel Johannes KOWALEWSKI ,  Michael ROEMER ,  Oliver SCHOOR

IPC: C07K14/725 ,  A61K35/17 ,  C07K14/74 ,  C07K16/28

CPC classification number: C07K14/7051 ,  A61K35/17 ,  C07K14/70539 ,  C07K16/2833 ,  A61K38/00

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240117004A1

公开(公告)日：2024-04-11

申请号：US18544048

申请日：2023-12-18

Applicant: Immatics Biotechnologies GmbH

Inventor： Jens HUKELMANN ,  Heiko SCHUSTER ,  Lena WULLKOPF ,  Christoph SCHRAEDER ,  Jens FRITSCHE ,  Daniel Johannes KOWALEWSKI ,  Michael ROEMER ,  Oliver SCHOOR

IPC: C07K14/725 ,  A61K35/17 ,  C07K14/74 ,  C07K16/28

CPC classification number: C07K14/7051 ,  A61K35/17 ,  C07K14/70539 ,  C07K16/2833 ,  A61K38/00

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240092933A1

公开(公告)日：2024-03-21

申请号：US18511308

申请日：2023-11-16

Applicant: Immatics Biotechnologies GmbH

Inventor： Gabriele PSZOLLA ,  Martin HOFMANN ,  Meike HUTT ,  Sebastian BUNK ,  Felix UNVERDORBEN ,  Frank SCHWOEBEL ,  Dominik MAURER ,  Maike JAWORSKI ,  Claudia WAGNER ,  Florian SCHWOERER ,  Heiko SCHUSTER

IPC: C07K16/30 ,  C07K16/28 ,  C07K16/46

CPC classification number: C07K16/30 ,  C07K16/2809 ,  C07K16/468 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/92

Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

公开(公告)号：US20240075130A1

公开(公告)日：2024-03-07

申请号：US18505361

申请日：2023-11-09

Applicant: Immatics Biotechnologies GmbH

Inventor： Jens HUKELMANN ,  Heiko SCHUSTER ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Frank SCHWOEBEL ,  Lena Katharina FREUDENMANN

IPC: A61K39/385 ,  A61K35/17 ,  A61K38/17 ,  A61K38/20 ,  A61P11/00 ,  A61P35/04 ,  A61P37/04 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783 ,  C12N5/10 ,  G01N33/574

CPC classification number: A61K39/385 ,  A61K35/17 ,  A61K38/1774 ,  A61K38/20 ,  A61K38/2046 ,  A61K38/2086 ,  A61P11/00 ,  A61P35/04 ,  A61P37/04 ,  C07K14/7051 ,  C07K16/2809 ,  C12N5/0638 ,  C12N5/10 ,  G01N33/57492 ,  A61K2039/53

Abstract: A method of treating a metastatic lesion that presents a peptide containing SLLQHLIGL (SEQ ID NO: 310) on a cell surface, including selecting a patient having a metastatic lesion and administering to the patient a composition containing recombinant T lymphocytes or activated T lymphocytes that express a T cell receptor, or a functional fragment thereof, that is reactive with, or binds to, an MHC ligand containing SLLQHLIGL (SEQ ID NO: 310).

公开(公告)号：US20240016911A1

公开(公告)日：2024-01-18

申请号：US18455685

申请日：2023-08-25

Applicant: Immatics Biotechnologies GmbH

Inventor： Jens HUKELMANN ,  Heiko SCHUSTER ,  Ricarda HANNEN ,  Christoph SCHRAEDER ,  Jens FRITSCHE ,  Franziska HOFFGAARD ,  Daniel Johannes KOWALEWSKI ,  Oliver SCHOOR

IPC: A61K35/17 ,  C07K14/725 ,  A61K45/06 ,  A61P37/04

CPC classification number: A61K35/17 ,  C07K14/7051 ,  A61K45/06 ,  A61P37/04

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240016909A1

公开(公告)日：2024-01-18

申请号：US18451883

申请日：2023-08-18

Applicant: Immatics Biotechnologies GmbH

Inventor： Jens HUKELMANN ,  Heiko SCHUSTER ,  Ricarda HANNEN ,  Christoph SCHRAEDER ,  Jens FRITSCHE ,  Franziska HOFFGAARD ,  Daniel Johannes KOWALEWSKI ,  Oliver SCHOOR

IPC: A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C07K14/74

CPC classification number: A61K39/0011 ,  A61P35/00 ,  C07K14/705 ,  C07K14/70539 ,  A61K39/00 ,  A61K2039/5158

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.